Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Targeted Degradation Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for APPBP1/NAE1 (NEDD8-activating enzyme E1 regulatory subunit) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | APPBP1/NAE1 Mutant & WT Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View APPBP1 Products |
| Gene Delivery | APPBP1/NAE1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View APPBP1 Products |
| Benchmark Ab | Anti-APPBP1 Benchmark Control Recombinant positive control for western/IP. |
View APPBP1 Products |
| Validator | APPBP1/NAE1 siRNA Set For knockdown verification. |
View APPBP1 Products |
| Related Target A | UBA3 Heterodimer catalytic partner required for NAE enzymatic activity. |
View UBA3 Products |
| Related Target B | NEDD8 Direct downstream substrate for neddylation cascade assays. |
View NEDD8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Active Complex Formation | Co-expressed NAE1/UBA3 heterodimers available, verified by Theoretical MW and strictly controlled aggregation. |
| Ubiquitin E1 Cross-reactivity | Homolog panel proteins (UBA1, SAE1) strictly verified by mass spec for counter-screening assays. |
| Lack of Controls | Clinical Benchmark antibodies and high-purity reference reagents included. |
| False Positives in Cell Assays | Validated siRNA included for specificity checks and pathway validation. |
Live APPBP1/NAE1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NEDD8-activating enzyme (NAE) therapeutics is intensifying as researchers look beyond early-generation small molecule inhibitors. While the neddylation pathway remains a highly validated target for disrupting Cullin-RING Ligase (CRL) function in hematological malignancies and solid tumors, the focus is shifting toward overcoming therapeutic index limitations. As first-generation therapies provide deep mechanistic insights, the next wave of R&D is targeting reversible inhibitors, allosteric modulators, and PROTAC-based degrader strategies to enhance tumor-specific vulnerability while sparing healthy tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Inhibitor) | Takeda, Taiho Oncology | AML, MDS, Solid Tumors | Enzymatic Selectivity Assay (Need high-purity NAE1/UBA3 vs UBA1) |
| PROTAC / Degrader | Academic / Biotech | Refractory Cancers | Ternary Complex Validation (Need Sequence Verified native targets) |
| Combination Therapy | Various | Immune-evasive Tumors | Pathway Inhibition Screening (Need reliable knockdown/siRNA tools) |